Serum Level of suPAR and YKL-40, a New Biomarker in Patients with Acute Myocardial Infarction?
MetadataShow full item record
Introduction: Low grade inflammation plays an important role in the several development process of coronary artery disease. The soluble urokinase plasminogen activator receptor (suPAR) and chitinase 3-like protein 1 (YKL-40) are the new potential biomarkers of inflammation. We intended to test the hypothesis whether the inflammatory biomarker YKL-40 alone or in combination with suPAR could be the new diagnostic biomarkers for acute myocardial infarction (AMI). Material and Methods: Fifty-five patients with AMI and seventy control subjects were included in the study. The diagnosis of AMI was based on the current 3rd standard universal definition criteria. Serum YKL-40 and suPAR levels were measured at the first and second days of AMI by using ELİSA method. Results: Serum YKL-40 levels were significantly higher in the first (69.10±16.58 ng/mL) and second day (60.64±16.01 ng/mL) of AMI patients than those of the control subjects (37.11±4.30 ng/mL) (p>0.001). Serum YKL-40 levels in the first day of AMI patients also were significantly higher than those of second day of AMI patients (p>0.01). Serum suPAR were significantly higher in the first (6.58±3.24 ng/mL) and second day (5.86±4.56 ng/mL) of AMI patients than those of the control subjects (2.26±1.92 ng/mL) (p>0.001). Conclusion: Serum suPAR and YKL-40 can be considered strong inflammatory markers of AMI. We concluded that serum suPAR and YKL-40 levels at the first day and second day of AMI could be used as a clinically useful marker for diagnosis of AMI.
SourceActa Medica Anatolia